EU’s Pharma Legislative Reform

While the outcome of the US presidential election is drawing most of the political attention these days, other political activity in Europe merits serious attention as well. Pharma reform legislation is moving forward in the EU that could significantly change everything from how firms manufacture their products to how much market exclusivity they get for them. These Pink Sheet stories break down the key issues, explaining what is already basically set and what remains undecided in this major initiative.

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.



Related resources

''
OCT 30, 2024
Article
薬事規制関連支援サービス

Artificial Intelligence Regulation

Drug sponsors strive to make the best use of artificial intelligence, but doing so requires understanding where health authorities are drawing the lines. Download a sample of our coverage from the US, Europe, and Asia of the emerging framework for AI regulation.

AI
OCT 11, 2024
Whitepaper
Clinical

AI in Pharma: Benefits, Risks, and the Road Ahead

AI is being used to streamline and accelerate each step of the drug development process from research through approval and marketing.

a person's hand holding a device with an AI interface
JUN 07, 2023
Article
商業化支援サービス

EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, and When?

Members of the European Parliament voted in favor of substantial changes to the draft AI Act, which has since been passed into law.